CASI Pharmaceuticals Inc (NASDAQ: CASI) kicked off on Monday, down -27.72% from the previous trading day, before settling in for the closing price of $1.84. Over the past 52 weeks, CASI has traded in a range of $1.63-$7.67.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 47.19% over the last five years. While this was happening, its average annual earnings per share was recorded 19.14%. With a float of $4.33 million, this company’s outstanding shares have now reached $15.49 million.
The firm has a total of 233 workers. Let’s measure their productivity. In terms of profitability, gross margin is 39.06%, operating margin of -138.02%, and the pretax margin is -133.4%.
CASI Pharmaceuticals Inc (CASI) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of CASI Pharmaceuticals Inc is 72.04%, while institutional ownership is 2.76%.
CASI Pharmaceuticals Inc (CASI) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 19.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.68% during the next five years compared to 11.81% growth over the previous five years of trading.
CASI Pharmaceuticals Inc (NASDAQ: CASI) Trading Performance Indicators
Take a look at CASI Pharmaceuticals Inc’s (CASI) current performance indicators. Last quarter, stock had a quick ratio of 0.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.69, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -1.63 in one year’s time.
Technical Analysis of CASI Pharmaceuticals Inc (CASI)
Analysing the last 5-days average volume posted by the [CASI Pharmaceuticals Inc, CASI], we can find that recorded value of 0.89 million was better than the volume posted last year of 51761.0. As of the previous 9 days, the stock’s Stochastic %D was 13.96%. Additionally, its Average True Range was 0.22.
During the past 100 days, CASI Pharmaceuticals Inc’s (CASI) raw stochastic average was set at 12.64%, which indicates a significant increase from 12.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 134.07% in the past 14 days, which was higher than the 79.80% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9109, while its 200-day Moving Average is $3.5113. Now, the first resistance to watch is $1.7867. This is followed by the second major resistance level at $2.2433. The third major resistance level sits at $2.5867. If the price goes on to break the first support level at $0.9867, it is likely to go to the next support level at $0.6433. Should the price break the second support level, the third support level stands at $0.1867.
CASI Pharmaceuticals Inc (NASDAQ: CASI) Key Stats
The company with the Market Capitalisation of 20.61 million has total of 12,299K Shares Outstanding. Its annual sales at the moment are 28,540 K in contrast with the sum of -39,260 K annual income. Company’s last quarter sales were recorded 6,240 K and last quarter income was -10,750 K.
